Ovid Therapeutics Inc. OVID 深 沪
已收盘 07-02 16:00:00 美东时间
2.69
+0.010
+0.37%
华盛通- 最 高2.795
- 今 开2.71
- 成交量 188.72万股
- 最 低 2.63
- 昨 收 2.68
- 总市值 5.02亿
- 52周最高 3.105
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 0.36
- 委 比 -78.28%
- 总股本 1.87亿
- 历史最高 15.89
- 量 比 0.31
- 振 幅 6.16%
- 历史最低 0.2425
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
uniQure N.V. (NASDAQ:QURE) on Friday reported initial six-month follow-up data from the first low-dose cohort in its ongoing Phase 1/2a trial evaluating investigational gene therapy candidate AMT-260 in patients with refractory mesial temporal lobe epilepsy (MTLE). MTLE represents the most prevalent...
06-22 23:51
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics announced that its management will participate in two upcoming investor conferences: the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 pm ET and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15. Presentations will be available via webcast on the company’s website at investors.ovidrx.com, with an archived replay for 30 days post-event.
06-04 11:00
Ovid Therapeutics Expands Board, Appoints New Scientific Director
Ovid Therapeutics ( ($OVID) ) has shared an announcement. On May 29, 2026, Ovid...
06-03 21:51
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
Ovid Therapeutics Inc. announced the appointment of Dr. Anna Greka as a new Board member, effective June 15, 2026. Dr. Greka, a renowned physician-scientist and entrepreneur, will Chair the Science and Technology Committee and join the Compensation Committee. Her expertise in ion channel biology and therapeutic innovation will support Ovid's development of KCC2 activators and epilepsy programs.
06-03 11:00
Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per share
05-12 19:21
Ovid Therapeutics Boosts Capital Through Warrant Exercises
The latest announcement is out from Ovid Therapeutics ( ($OVID) ). On April 17,...
04-20 20:52
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $2 to $4.
04-09 19:32
